(Boston) – A team of researchers at Boston University School of Medicine (BUSM) have been awarded a five-year, $7.7 million grant from the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to explore how chronic inflammation can lead to systemic diseases. Caroline Genco, PhD, director of research in the section of infectious diseases and professor of medicine and microbiology at BUSM, is the principal investigator on the grant. She will lead a multidisciplinary research team as they study the cellular mechanisms responsible for immune system activation, which induces chronic inflammation following bacterial infection.
Inflammation, which is the body's biological response to infection, initiates the healing process. In most cases, infections with pathogens, including bacteria, result in attack by the immune system and clearance of the pathogen. However, certain types of bacteria persist in the body for long periods of time, causing sub acute chronic infections. During that time, they cause inflammation, which can lead to systemic diseases.
This study focuses on two pathogens, Chlamydophila pneumoniae and Porphyromanas gingivalis, which induce a chronic inflammatory response in the lungs and the mouth, respectively. The chronic inflammation can lead to atherosclerosis, or hardening of the arteries, as a result of plaque buildup.
"The goal of this study is to understand how these pathogens persist and cause inflammation that can eventually lead to disease," said Genco. "The immune system exists to protect us, yet in some circumstances, it has harmful effects and contributes to systemic inflammatory diseases. We are investigating what goes awry in this complex system so that we can identify what mechanisms are responsible for these detrimental health outcomes."
Other researchers at BUSM involved include Robin Ingalls, MD, Frank Gibson, PhD, Guillermo Madico, MD, PhD, and Lee Wetzler, MD, all from the section of infectious diseases; Jane Freedman, MD, and Ellen Weinberg, PhD, of Boston Medical Center's section of cardiology and vascular medicine; James Hamilton, PhD, from the department of physiology & biophysics at BUSM and biomedical engineering at Boston University's College of Engineering; and Michael Lavalley, PhD, of Boston University's School of Public Health.
This project is supported by NIH's National Institute of Allergy and Infectious Diseases, award number P01AI078894. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIAID or the NIH.
About Boston University School of Medicine
Originally established in 1848 as the New England Female Medical College, and incorporated into Boston University in 1873, Boston University School of Medicine today is a leading academic medical center with an enrollment of more than 700 medical students and more than 800 masters and PhD students. Its 1,246 full and part-time faculty members generated more than $335 million in funding in the 2009-2010 academic year for research in amyloidosis, arthritis, cardiovascular disease, cancer, infectious disease, pulmonary disease and dermatology among others. The School is affiliated with Boston Medical Center, its principal teaching hospital, the Boston and Bedford Veterans Administration Medical Centers and 16 other regional hospitals as well as the Boston HealthNet.